XLO
- Xilio Therapeutics, Inc.
()
Overview
Company Summary
Xilio Therapeutics, Inc. is a biotechnology company that specializes in developing novel cancer immunotherapies. The company focuses on engineering a new class of therapeutic molecules called tumors-selective immune modulators (TSIMs) to activate and enhance the body's immune response against cancer cells.
Xilio's TSIMs are designed to selectively target and activate immune cells within the tumor microenvironment while minimizing unwanted systemic immune activation. By doing so, these therapies aim to overcome the immunosuppressive barriers present in many solid tumors.
The company's proprietary technology platform combines insights from tumor immunology, bioengineering, and synthetic biology to design and develop TSIMs that can be delivered directly to the tumor site. This localized delivery approach potentially maximizes therapeutic efficacy while minimizing potential side effects associated with systemic immune activation.
Xilio Therapeutics is in the early stages of developing its product pipeline and collaborating with leading academic institutions and research organizations to advance its technology. The ultimate goal is to create innovative cancer immunotherapies that can significantly improve patient outcomes and potentially transform the way cancer is treated.